Searched for: person:panc01
in-biosketch:true
Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy-A New Horizon in Hepatitis B Therapy. Authors' Reply [Letter]
Pan, Xingfei; Pan, Calvin Q
PMID: 40462557
ISSN: 1365-2036
CID: 5862332
Chronic Kidney Disease in Isolated Core Antibody Positive Hepatitis B Patients: Risk Analysis from NHANES 2017-2020 Study: HBV infection and CKD risk
Mi, Ke; Ye, Tingdan; Pan, Calvin Q
BACKGROUND:The association between isolated hepatitis B core antibody (HBcAb) positivity and chronic kidney disease (CKD) remains debated. While some studies suggest HBV infection increases CKD risk, others report inconclusive findings. This study evaluated the association between isolated HBcAb positivityand CKD in the U.S. METHODS:Data from adult participants in the NHANES 2017-2020 pre-pandemic cycle were analyzed based on prespecified eligibility criteria. Participants were categorized into isolated HBcAb positive and non-infected groups. Weighted means and percentages described participant characteristics, while logistic regression models evaluated the association between isolated HBcAb positive and CKD. Multivariate logistic regression identified CKD risk factors among isolated HBcAb positive individuals. RESULTS:Among 7,582 participants (7072 non- infected and 510 isolated HBcAb positive), CKD prevalence was higher in isolated HBcAb positive individuals (7.9% vs. 5.2%, P = 0.018). Unadjusted analyses showed isolated HBcAb positivity increased CKD risk (OR = 1.25, 95% CI: 1.04-1.50, P = 0.019). However, adjusted analyses revealed an inverse association (OR = 0.76, 95% CI: 0.60-0.98, P = 0.034). In isolated HBcAb positive individuals, older age (OR = 1.06, P = 0.017) and serum urea nitrogen (BUN) elevation (OR = 1.20, P = 0.001) were associated with higher CKD risk, while higher education lever reduced the risk (OR = 0.28, P = 0.030). CONCLUSION/CONCLUSIONS:Although CKD prevalence was higher in isolated HBcAb positive patients, There was no positive association between isolated HBcAb positivity and CKD. Older age and elevated BUN levels were significantly associated with higher CKD risk, while elevated education lever reduced the risk. These findings highlight the needs for individualized monitoring and management of at-risk HBV-infected patients when offering antiviral therapy and monitoring after clinical cure of hepatitis B.
PMID: 40441603
ISSN: 2210-741x
CID: 5854832
Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
Pan, Xingfei; Zhou, Liyang; Hu, Jing; Zhai, Panpan; Ou, Xueting; He, Fang; Pan, Calvin Q
BACKGROUND:Mothers with chronic hepatitis B and advanced fibrosis may require antiviral therapy throughout pregnancy. Current guidelines recommend tenofovir disoproxil fumarate (TDF), which is unsuitable for mothers at risk of renal dysfunction or decreased bone mineral density. AIMS/OBJECTIVE:This study aimed to evaluate the safety of tenofovir alafenamide (TAF) therapy during pregnancy. METHODS:Mothers with chronic hepatitis B treated with TAF or no therapy were retrospectively enrolled and categorised into three groups: (A) TAF-first trimester, (B) TAF-late trimester and (C) no treatment. Propensity score matching was applied to create comparable groups. Primary assessments included serious adverse events up to postpartum week 28, while secondary assessments examined predictors of such events and vertical transmission rates. RESULTS:Among 284 mothers, 160 were selected. No significant differences were observed in foetal loss, low birth weight, preterm delivery or congenital abnormalities between groups A and B, or between groups A and C. Other adverse events were similar across groups, except for a higher incidence of gestational diabetes in the TAF-first trimester group. In vitro fertilisation was identified as the sole predictor of serious events. No infants were reported with hepatitis B virus infection at 28 weeks postpartum. CONCLUSIONS:This study suggests that TAF treatment throughout pregnancy is safe for mothers with chronic hepatitis B and their infants. TAF therapy represents a viable treatment option for these mothers.
PMID: 40318163
ISSN: 1365-2036
CID: 5834752
Global Burden of Major Chronic Liver Diseases in 2021
Feng, Gong; Yilmaz, Yusuf; Valenti, Luca; Seto, Wai-Kay; Pan, Calvin Q; Méndez-Sánchez, Nahum; Ye, Feng; Sookoian, Silvia; Targher, Giovanni; Byrne, Christopher D; Chan, Wah-Kheong; Treeprasertsuk, Sombat; Yu, Hon Ho; Kim, Seung Up; George, Jacob; Xu, Wen-Jing; Sebastiani, Giada; Ocama, Ponsiano; Ryan, John D; Lupșor-Platon, Monica; Ghazinyan, Hasmik; Hamid, Saeed; Perera, Nilanka; Alswat, Khalid; Isakov, Vasily; Pan, Qiuwei; Sarin, Shiv Kumar; Schattenberg, Jörn M; Sotoudeheian, Mohammadjavad; Wong, Yu Jun; Sharara, Ala I; Al-Busafi, Said A; Opio, Christopher Kenneth; Chai, Jin; Fouad, Yasser; Shi, Yu; Al-Mahtab, Mamun; Zhang, Sujuan; Pirola, Carlos Jose; Wong, Vincent Wai-Sun; Zheng, Ming-Hua
BACKGROUND:This study utilised the Global Burden of Disease data (2010-2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver disease, cirrhosis and other chronic liver diseases. METHODS:Age-standardised rates per 100,000 population for prevalence, annual incidence and YLDs were compared across regions and countries, as well as the socio-demographic index (SDI). Trends were expressed as percentage changes (PC) and estimates were reported with uncertainty intervals (UI). RESULTS:Globally, in 2021, the age-standardised rates per 100,000 population for the prevalence of hepatitis B, hepatitis C, MASLD and cirrhosis and other chronic liver diseases were 3583.6 (95%UI 3293.6-3887.7), 1717.8 (1385.5-2075.3), 15018.1 (13756.5-16361.4) and 20302.6 (18845.2-21791.9) respectively. From 2010 to 2021, the PC in age-standardised prevalence rates were-20.4% for hepatitis B, -5.1% for hepatitis C, +11.2% for MASLD and + 2.6% for cirrhosis and other chronic liver diseases. Over the same period, the PC in age-standardized incidence rates were -24.7%, -6.8%, +3.2%, and +3.0%, respectively. Generally, negative associations, but with fluctuations, were found between age-standardised prevalence rates for hepatitis B, hepatitis C, cirrhosis and other chronic liver diseases and the SDI at a global level. However, MASLD prevalence peaked at moderate SDI levels. CONCLUSIONS:The global burden of chronic liver diseases remains substantial. Hepatitis B and C have decreased in prevalence and incidence in the last decade, while MASLD, cirrhosis and other chronic liver diseases have increased, necessitating targeted public health strategies and resource allocation.
PMID: 40062742
ISSN: 1478-3231
CID: 5808172
Vertical Transmission in Mothers Taking TAF With Exceptionally High Viral Load
Zou, Huaibin; Zhu, Liying; Cao, Lihua; Suo, Shuyi; Zhu, Yunxia; Wang, Yuanyuan; Dong, Jingchao; Han, Baiyila; Duan, Zhongping; Chen, Yu; Pan, Calvin Q
Published studies on tenofovir alafenamide (TAF) therapy for preventing vertical transmission of hepatitis B virus (HBV) have primarily enrolled mothers with viremic levels of approximately 7 log10 IU/mL. This study aimed to evaluate the efficacy and safety of TAF therapy in preventing mother-to-child transmission (MTCT) in mothers with exceptionally high viral loads, defined as HBV DNA levels > 2,000,000 IU/mL. Hepatitis B e antigen (HBeAg)-positive mothers with HBV DNA levels > 2,000,000 IU/mL were prospectively enrolled from four hospitals and initiated on TAF therapy between gestational weeks 26 and 28, continuing until delivery. All infants received immunoprophylaxis and were followed up to 28 weeks postpartum. The primary endpoints were the MTCT rate and the occurrence of congenital abnormalities in infants. Secondary outcomes included maternal HBV suppression at delivery and the safety of both mothers and infants. Among 137 mothers screened, 120 were enrolled in TAF therapy, and 121 infants completed the study. At delivery, 93.3% (112/120) of mothers achieved HBV DNA levels < 200,000 IU/mL. At birth, 0.8% (1/121) of infants had a congenital malformation, and 9.9% (12/121) tested positive for HBsAg. The vertical transmission rate was 2% (2/121, intention-to-treat) at 28 weeks of age. No severe adverse effects were reported in mothers or infants. On-treatment and postpartum alanine aminotransferase (ALT) flares after TAF cessation occurred in 7.5% (9/120) and 41.1% (46/112) of mothers, respectively, alongside viral rebound after cessation. Infant physical development remained within normal ranges based on national reference standards. In summary, approximately 2% of mothers on TAF therapy during late pregnancy experienced MTCT, despite proper immunoprophylaxis for their infants. Extending the treatment duration beyond 12 weeks for mothers with extremely high viral loads is recommended to improve MTCT prevention. No safety concerns were observed for either mothers or infants. Trial Registration: ClinicalTrials.gov identifier: NCT04237376.
PMID: 39953819
ISSN: 1365-2893
CID: 5794062
Hepatic lipid metabolism is altered in Ubiad1+/- mice of both sexes
Higa, Ryoko; Pourteymour, Shirin; Kolan, Pratibha S; Dankel, Simon N; Fernø, Johan; Mellgren, Gunnar; Pan, Calvin; Seldin, Marcus M; Lusis, Aldons J; Drevon, Christian A; Dalen, Knut T; Norheim, Frode A
UbiA prenyltransferase domain containing 1 (Ubiad1) has the potential to affect cholesterol and phospholipid levels in different cell types. We previously identified Ubiad1 as a candidate gene for regulating subcutaneous fat pad weight in a mouse genome-wide association study. Here we evaluated the relationship between Ubiad1 and obesity-related traits in cohorts of humans and mice, and in Ubiad1+/- mice fed a high-fat diet. In both humans and mice, adipose tissue Ubiad1 mRNA expression correlated negatively with adiposity and positively with mitochondria-related genes. To determine the role of Ubiad1 in high-fat diet-induced obesity, we disrupted the Ubiad1 gene in mice. Deletion of Ubiad1 was embryonically lethal in C57BL/6 N mice, preventing analysis of adult Ubiad1-/- mice. Thus, male and female Ubiad1+/+ and Ubiad1+/- mice were fed high-fat diet for 10 weeks, with no difference in weight gain and adipose tissue organ weights observed between the genotypes. Analysis of liver mRNA expression revealed that Ubiad1 heterozygosis (Ubiad1+/-) altered several pathways involved in lipid metabolism. Detailed lipid quantification with HPLC-qTOF/MS showed increased levels of hepatic ceramides in female Ubiad1+/- mice, whereas phosphatidylglycerols, phosohatidylinositol and lysophosphatidylethanolamines were reduced in male Ubiad1+/- mice. Our findings reveal sex-specific effects of Ubiad1 expression on hepatic lipid metabolism.
PMCID:11868635
PMID: 40016272
ISSN: 2045-2322
CID: 5801272
Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial
Pan, Calvin Q; Dai, Erhei; Mo, Zhongfu; Zhang, Hua; Zheng, Thomas Q; Wang, Yuming; Liu, Yingxia; Chen, Tianyan; Li, Suwen; Yang, Cuili; Wu, Jinjuan; Chen, Xiuli; Zou, Huaibin; Mei, Shanshan; Zhu, Lin
IMPORTANCE/UNASSIGNED:Standard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas. OBJECTIVE/UNASSIGNED:To determine whether initiating tenofovir disoproxil fumarate (TDF) at gestational week 16 combined with HBV vaccinations for infants is noninferior to the standard care of TDF at gestational week 28 combined with HBV vaccinations and HBIG for infants in preventing MTCT in mothers with HBV and high levels of viremia. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:An unblinded, 2-group, randomized, noninferiority clinical trial was conducted in 7 tertiary care hospitals in China. A total of 280 pregnant individuals (who all identified as women) with HBV DNA levels greater than 200 000 IU/mL were enrolled between June 4, 2018, and February 8, 2021. The final follow-up occurred on March 1, 2022. INTERVENTIONS/UNASSIGNED:Pregnant individuals were randomly assigned to receive either TDF starting at gestational week 16 with HBV vaccinations for the infant or TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant. MAIN OUTCOMES AND MEASURES/UNASSIGNED:The primary outcome was the MTCT rate, defined as detectable HBV DNA greater than 20 IU/mL or hepatitis B surface antigen positivity in infants at age 28 weeks. Noninferiority was established if the MTCT rate in the experimental group did not increase by more than an absolute difference of 3% compared with the standard care group, as measured by the upper limit of the 2-sided 90% CI. RESULTS/UNASSIGNED:Among 280 pregnant individuals who enrolled in the trial (mean age, 28 years; mean gestational age at enrollment, 16 weeks), 265 (95%) completed the study. Among all live-born infants, using the last observation carried forward, the MTCT rate was 0.76% (1/131) in the experimental group and 0% (0/142) in the standard care group. In the per-protocol analysis, the MTCT rate was 0% (0/124) in the experimental group and 0% (0/141) in the standard care group. The between-group difference was 0.76% (upper limit of the 2-sided 90% CI, 1.74%) in all live-born infants and 0% (upper limit of the 2-sided 90% CI, 1.43%) in the per-protocol analysis. Both comparisons met the criterion for noninferiority. Rates of congenital defects and malformations were 2.3% (3/131) in the experimental group and 6.3% (9/142) in the standard care group (difference, 4% [2-sided 95% CI, -8.8% to 0.7%]). CONCLUSIONS AND RELEVANCE/UNASSIGNED:Among pregnant women with HBV and high levels of viremia, TDF beginning at gestational week 16 combined with HBV vaccination for infants was noninferior to the standard care of TDF beginning at gestational week 28 combined with HBIG and HBV vaccination for infants. These results support beginning TDF at gestational week 16 combined with infant HBV vaccine to prevent MTCT of HBV in geographic areas where HBIG is not available. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT03476083.
PMCID:11565373
PMID: 39540799
ISSN: 1538-3598
CID: 5753442
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
Razavi, Homie A; Waked, Imam; Qureshi, Huma; Kondili, Loreta A; Duberg, Ann-Sofi; Aleman, Soo; Tanaka, Junko; Lazarus, Jeffrey V; Low-Beer, Daniel; Abbas, Zaigham; Rached, Antoine Abou; Aghemo, Alessio; Aho, Inka; Akarca, Ulus S; Al-Busafi, Said A; Al-Hamoudi, Waleed K; Al-Naamani, Khalid; Alaama, Ahmed Sabry; Aldar, Manahil M; Alghamdi, Mohammed; Gonzalez, Monica Alonso; Alserehi, Haleema; Anand, Anil C; Asselah, Tarik; Assiri, Abdullah M; Athanasakis, Kostas; Atugonza, Rita; Ben-Ari, Ziv; Berg, Thomas; Brandão-Mello, Carlos E; Brown, Ashley S M; Brown, Kimberly A; Brown, Robert S; Bruggmann, Philip; Brunetto, Maurizia R; Buti, Maria; Cheinquer, Hugo; Christensen, Peer Brehm; Chulanov, Vladimir; Cisneros Garza, Laura E; Coffin, Carla S; Coppola, Nicola; Craxi, Antonio; Crespo, Javier; Cui, Fuqiang; Dalgard, Olav; De La Torre, Alethse; De Ledinghen, Victor; Dieterich, Douglas; Drazilova, Sylvia; Dufour, Jean-François; El-Kassas, Mohamed; Elbadri, Mohammed; Esmat, Gamal; Mur, Rafael Esteban; Eurich, Brandon; Faini, Diana; Ferreira, Paulo R A; Flisiak, Robert; Frankova, Sona; Gaeta, Giovanni B; Gamkrelidze, Ivane; Gane, Edward J; Garcia, Virginia; García-Samaniego, Javier; Gemilyan, Manik; Gottfredsson, Magnus; Gschwantler, Michael; Gurski, Ana P M; Hajarizadeh, Behzad; Hamid, Saeed S; Hatzakis, Angelos; Hercun, Julian; Hockicková, Ivana; Huang, Jee-Fu; Hunyady, Bela; Hutchinson, Sharon J; Ishikawa, Naoko; Izumi, Kiyohiko; Izzi, Antonio; Janicko, Martin; Jarcuska, Peter; Jeruma, Agita; Johannessen, Asgeir; Kaliaskarova, Kulpash S; Kao, Jia-Horng; Kielland, Knut B; Kodjoh, Nicolas; Kottilil, Shyamasundaran; Kristian, Pavol; Kwo, Paul Y; Lagging, Martin; Lam, Hilton; Lázaro, Pablo; Lee, Mei-Hsuan; Lens, Sabela; Liakina, Valentina; Lim, Young-Suk; Makara, Michael; Manns, Michael; Manzengo, Casimir Mingiedi; Memon, Sadik; Mendes-Correa, Maria Cássia; Messina, Vincenzo; Midgard, Håvard; Murphy, Niamh; Musabaev, Erkin; Naveira, Marcelo C M; Nde, Helen; Negro, Francesco; Nim, Nirada; Ocama, Ponsiano; Olafsson, Sigurdur; Omuemu, Casimir E; Pamplona, Javier J; Pan, Calvin Q; Papatheodoridis, George V; Pimenov, Nikolay; Poustchi, Hossein; Quaranta, Maria Giovanna; Ramji, Alnoor; Rautiainen, Henna; Razavi-Shearer, Devin M; Razavi-Shearer, Kathryn; Ridruejo, Ezequiel; Ríos-Hincapié, Cielo Y; Sadirova, Shakhlo; Sanai, Faisal M; Sarrazin, Christoph; Sarybayeva, Gulya; Schréter, Ivan; Seguin-Devaux, Carole; Sereno, Leandro S; Shiha, Gamal; Smith, Josie; Soliman, Riham; Sonderup, Mark W; Spearman, C Wendy; Stauber, Rudolf E; Stedman, Catherine A M; Sypsa, Vana; Tacke, Frank; Terrault, Norah A; Tolmane, Ieva; Van Welzen, Berend; Voeller, Alexis S; Waheed, Yasir; Wallace, Carolyn; Whittaker, Robert N; W-S Wong, Vincent; Ydreborg, Magdalena; Yesmembetov, Kakharman; Yu, Ming-Lung; Zeuzem, Stefan; Zuckerman, Eli
BACKGROUND AND AIMS/OBJECTIVE:The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization's 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases. METHODS:The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used. RESULTS:An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program. CONCLUSIONS:In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies. IMPACT AND IMPLICATIONS/UNASSIGNED:Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.
PMID: 39914746
ISSN: 1600-0641
CID: 5784292
Patient-reported outcomes in mothers with chronic hepatitis B infection: A cross-sectional analysis
OuYang, Shi; Deng, Yueying; Geng, Yawen; Yuan, Xiaoli; Peng, Tingting; Qiu, Junchao; Xiao, Zhirong; Yan, Shengguang; Deng, Haitao; Peng, Xiaotong; Pan, Calvin Q
BACKGROUND & AIMS/OBJECTIVE:The health-related quality of life (HRQoL) during pregnancy has not been well-lidated in mothers with chronic hepatitis B (CHB). We aim to compare patient-reported outcomes (PROs) in CHB mothers with those of healthy mothers during pregnancy. METHODS:Between 4/16/2023 and 7/31/2023, we invited consecutive CHB and healthy mothers to complete the self-administered 36-item Short Form Survey (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) for PRO assessment. Pairwise comparisons of PRO scores between groups were performed using chi-square tests. Covariates for worse PROs were further analyzed by the multiple linear regression model to identify the independent predictors RESULTS: Among 257 participants (CHB: healthy control was 100:157), the mean (SD) age was 29.6 (3.4), and the majority completed the PRO assessment at the gestational weeks of 16-24. When compared to healthy mothers, CHB mothers had a significant impairment of PROs in the CLDQ domain of worry (6.97±0.16 vs 5.83±0.99, p<0.05) and the SF-36 domain of social functioning (95.33±10.00 vs 91.67±16.37, p<0.05). The subgroup analyses in CHB mothers showed HBV DNA >200,000 IU/mL associated with significantly worse PROs. The multivariate analyses identified CHB infection, severe nausea or vomiting, poor living conditions, and spousal negative attitude as independent predictors of HRQoL impairment. CONCLUSION/CONCLUSIONS:This study suggests that CHB infection during pregnancy negatively impacted HRQoL, particularly in worry and social functioning domains. CHB infection was an independent predictor for PRO impairments. Further integration of monitoring and intervention on HRQoL impairment should be considered when managing CHB mothers during pregnancy.
PMID: 39870348
ISSN: 2210-741x
CID: 5780622
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Buti, Maria; Lim, Young-Suk; Chan, Henry Lik Yuen; Agarwal, Kosh; Marcellin, Patrick; Brunetto, Maurizia R; Chuang, Wan-Long; Janssen, Harry L A; Fung, Scott K; Izumi, Namiki; Jablkowski, Maciej S; Abdurakhmanov, Dzhamal; Abramov, Frida; Wang, Hongyuan; Botros, Irina; Yee, Leland J; Mateo, Roberto; Flaherty, John F; Osinusi, Anu; Pan, Calvin Q; Shalimar, X; Seto, Wai-Kay; Gane, Edward J
BACKGROUND:In two phase 3 studies, tenofovir alafenamide (TAF) showed non-inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB). AIMS/OBJECTIVE:Here, we report the studies' final 8-year results. METHODS:CHB patients (hepatitis B e antigen [HBeAg]-negative and HBeAg-positive) were randomised (2:1) to double-blind TAF 25 mg/day or TDF 300 mg/day for up to 3 years, followed by open-label (OL) TAF through year 8. Virological, biochemical, serological and fibrosis responses, and safety, including bone and renal parameters, were evaluated. Resistance to TAF was assessed annually by deep sequencing of polymerase/reverse transcriptase and by phenotyping. RESULTS:and hip/spine BMD observed during double-blind TDF improved after switching to OL TAF. No patients developed resistance to TAF. CONCLUSION/CONCLUSIONS:Long-term TAF treatment exhibited favourable safety and tolerability with high rates of viral suppression and no development of resistance. CLINICALTRIALS/RESULTS:gov numbers NCT01940341 and NCT01940471.
PMCID:11599788
PMID: 39327857
ISSN: 1365-2036
CID: 5763322